biomx presentation no numbers - Phage...
25
Microbiome Modulation Assaf Oron, CBO Biomed Conference Tel Aviv, May 2017 May 2017
Transcript of biomx presentation no numbers - Phage...
Microbiome Modulation
Assaf Oron, CBO
Biomed Conference
Tel Aviv, May 2017
May 2017
Microbiome – A revolutionary cure
Linda, lives in California
● 2010 – Was treated with antibiotics due to a
severe urinary tract infection
● Soon after – Tested positive for C. Diff.
● 2010– 2014
● Multiple Antibiotics – Flagyl, Vanomycin
● Vitamin supplements, probiotics
● 2014 – Linda underwent Fecal Microbiota
Transplantation (FMT) and was cured
“I lost 68 pounds in 4 years”
Microbiome – A revolutionary cure
Our Microbiome
We have > X100 microbial genes than human genes
Our Microbiome –Microbials (mainly
bacteria) that reside in/on our body
Human DNA – 99.9% identical Microbiome DNA – 80-90% identical
“Obesity alters gut microbial ecology”
“Gut Bacteria Shakes up Cancer Research”
“Microbiome Bacterial imbalance in Crohn’s disease”
“Microbial cocktails join fecal transplants in IBD”
The Microbiome plays a vital role and interventions are paving a path forward
Google trends – ‘Microbiome’
20162012 2013 2014 20152011
Microbiome – Can it cure obesity?
MicrobiotaTransplant
MicrobiotaTransplant
Microbiome – Industry
License to C. Diff. Phase II candidate and other - $120M upfront + $660M MS + Royl.
Vedanta license IBD Pre-clinical product to Janssen
We develop novel therapeutics to alleviate microbiome-related
diseases using our 3-tier Microbiome Modulation Platform, devised by
world-leading scientists
BiomX Mission
BiomX at a Glance
· Founded 2015
· Based in Israel
· >20 Employees
Establishment
· P. acnes – Pre-Clinical
· IBD – Pre-Clinical
· GI tract associated Cancers – PhageDiscovery
· Immune oncology – Target Discovery
PipelineInvestors
Technology
· Completed $24 M series A
FinancingScientific Founders
Our 3-Tier Microbiome Modulation Platform:
· Target Bacteria Discovery
· Microbiome Modulation
· Drug Development
·Prof. Rotem Sorek, Weizmann Institute - Expert in phage biology
·Dr. Expert in phage biology, Leader in microbiome research
·Prof. Timothy K, Lu, MIT -Leader in phage engineering therapeutics
Dr. Eran Elinav MD, PhD
·Developed unique mouse models and humanized mice
·World leader in microbiome research
·Published in Cell, Science
Prof. Timothy K. Lu MD, PhD
·Extensive work with engineered bacteriophage therapeutics for antibiotic-resistant infection
· World leader in synthetic biology
· Published in Nature, Science
Prof. Rotem Sorek PhD
·Expert in phage biology and massive genome analyses
·World leader in CRISPR research
·Published in Nature, Science
Groundbreaking research from BiomX founders has unlocked a Broad microbiome drug potential
Our 3-TierMicrobiome Modulation Platform
Target Bacteria
Discovery
Microbiome
Modulation
Product
Development
Target bacteria discovery
Target Bacteria
Discovery
100
trillion
bacteria
Target bacteria discovery
Target Bacteria
Discovery
>1,000
species
Target bacteria discovery
Target Bacteria
Discovery
10,000’s
strains
Target bacteria discovery
Target Bacteria
Discovery
✓
Add Stimuli
Target bacteria discovery
Target Bacteria
Discovery
✓
X
✓
Target bacteria discovery
X
✓
Microbiome
Modulation
Eradicate – Phage Discovery
A proprietary high throughput
platform for natural and synthetic
phage discovery
Viral Genome
Tail Fiber
17
2
3
45
6 A BACTERIOPHAGE IS A
VIRUS THAT INFECTS ONLY
A SPACIFIC BACTERIUM
1 LOCATE
2 INJECT
3 INFECT
4 MULTIPLY
5 ASSEMBLE
6 ERADICATE
7 SEEK
Bacteriophage cocktails as therapeutic agent
Target bacteria discovery
X
✓
Microbiome
Modulation
Eradicate – Phage Discovery
A proprietary high throughput
platform for natural and synthetic
phage discovery
Add Bacteria
Culturing, stability, reproducibility
Target bacteria discovery
In – Vivo testing
Advanced In-Vitro/Ex-Vivo testing
Process development
Formulation
Production
Regulatory
Product
Development
BX001 spray dried Dissolution Formulation Dissolution
Phage formulation in collaboration with Takeda
End-to-endMicrobiome Modulation Platform
Target Bacteria
Discovery
Microbiome
Modulation
Product
Development
A broad & diverse pipeline
ACNE BX001
Step 1TARGET DISCOVERY
Step 2MICROBIOME MODULATION
Step 3PRE-CLINICAL DEVELOPMENT
Step 4CLINICAL DEVELOPMENT
IBD (INFLAMMATORY BOWEL DISEASE) BX002
GI associated Cancers Harnessing Synthetic Biology
IMMUNO-ONCOLOGY Checkpoint Inhibitors
Acne BX001
$5.1B Acne Therapy Market
An opportunity for novel
alternatives to antibiotics
* 2017 total acne therapy market forecast, Acne Treatment Market: Global Industry Analysis and Forecast, 2017 – 2025, Persistence Market Research
BX001 on a lawnof P. acnes
Black – Where gel with BX001 was applied
Red – Area of phage activity (eradicated P.acnes)
· Target what’s needed, not damaging good bacteria
· Address antibiotic resistance
· Self replicating –
Increased activity in site
A topical gel of a proprietary phage cocktail
1
2
3
IBD BX002
$8B IBD therapy market
* CCFA – Crohn’s & Colitis Foundation of America. Visiongain IBD report 2016-2026
BX002 eradicated specific IBD inducing bacteria Bacteria eradicated:
· Novel, specific IBD induction path
· Demonstrate IBD induction in-vivo
· Antibiotic resistant
Clear evidence that gut bacteria impacts IBD
A phage cocktail eradicating IBD inducing bacteria
1
2
30
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.00 2.00 4.00 6.00 8.00D
en
sity
(O
D 6
00
nm
)
Time (Hrs)
Red – Control, only bacteria
Green – Bacteria + BX002
Thank You !
Visit us at www.biomx.com
May 2017
